Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03093155 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
A Phase 2 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
- 2
- Study locations
NCT03093155: Completed Phase 2 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, sponsored by Yale University.
NCT03093155 is a Phase 2 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer that has completed, run by Yale University. The registered enrollment target is 78 participants, below the 255-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (69% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03093155, a Phase 2 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a randomized, two-arm, open-label Phase II multicenter study designed to examine the effects of adding bevacizumab to ixabepilone for the treatment of patients who have recurrent or persistent platinum-resistant/refractory epithelial (non-mucinous) ovarian, fallopian tube, or primary peritoneal cancer. Its primary objective is to assess whether adding bevacizumab to ixabepilone improves progression-free survival in its target population. Study participants will be stratified by (a) study site and (b) previous receipt of bevacizumab prior to randomization.
Primary Outcome
Progression-free survival (PFS), the primary endpoint, will be defined as the length of time from randomization to disease recurrence, disease progression, or death for any reason. The timeframe was updated upon results entry.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Ixabepilone
Study Locations (2)
Connecticut
- Smilow Cancer Hospital at Yale New Haven - New Haven
Maryland
- Marlene & Stewart Greenebaum Comprehensive Cancer Center, University of Maryland - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2017-04-03 |
| Est. Completion | 2022-12-29 |
| Phase | Phase 2 |
What the finished NCT03093155 record still lists
NCT03093155 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 255-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (69% lower).
The record links to 3 conditions, with Fallopian Tube Cancer appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT03093155 reports a single indexed study location in Connecticut, Maryland.
Frequently Asked Questions
What is clinical trial NCT03093155 about?
NCT03093155 is a clinical study titled "Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab". This is a randomized, two-arm, open-label Phase II multicenter study designed to examine the effects of adding bevacizumab to ixabepilone for the treatment of patients who have recurrent or persistent platinum-resistant/refractory epithelial (non-mucinous) ovarian, fallopian tube, or primary periton...
What is the current status of trial NCT03093155?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2017-04-03. Estimated completion is 2022-12-29.
What conditions does trial NCT03093155 study?
This clinical trial studies the following conditions: Fallopian Tube Cancer, Epithelial Ovarian Cancer, Primary Peritoneal Cancer.
What interventions are being tested in trial NCT03093155?
The interventions under investigation include: Bevacizumab (DRUG), Ixabepilone (DRUG).
Who is sponsoring clinical trial NCT03093155?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03093155 being conducted?
This trial has 2 study locations across Connecticut, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fallopian Tube Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03093155's enrollment target sits among peer trials
78 40th of 85 higher than 46 of 85 other Fallopian Tube Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fallopian Tube Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
-
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
RECRUITING · Phase 2
-
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RECRUITING · Phase 2
-
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI